High importance
Oct 8, 2026
Understanding the complications associated with HHT, especially in patients with mutations such as SMAD4 and ENG, is critical for managing symptoms like hemoptysis and preventing severe outcomes. This case underscores the necessity for vigilant monitoring and innovative treatment approaches in managing complex AVMs in HHT patients.
To report and discuss a rare case of hemoptysis in a patient with a significant medical history related to Hereditary Hemorrhagic Telangiectasia (HHT), specifically focusing on the implications of SMAD4 and ENG mutations.
The patient was found to have ongoing hemoptysis linked to unresolved pulmonary AVMs, contributing to his pulmonary symptoms. Treatment strategies were considered, including possible surgical intervention and further embolization.
Clinical evaluation of the patient's history, physical examination, and imaging studies to ascertain the cause of hemoptysis, especially in the context of existing pulmonary arteriovenous malformations (AVMs) and previous embolization treatments.
The case primarily illustrates a single patient's experience; therefore, broader conclusions about treatment efficacy and outcomes in similar patients with HHT are limited. The rarity of such cases makes it difficult to generalize findings.
For your doctor:
PMID: 42850011
DOI: 10.1016/j.chest.2026.04.037
A 23-year-old man with a medical history significant for juvenile polyposis-hereditary hemorrhagic telangiectasia (SMAD4 and ENG mutation-positive), multiple prior coil embolizations for pulmonary arteriovenous malformations, and recurrent epistaxis refractory to nasal cauterization presented to the emergency department with 1 week of cough and 2 days of hemoptysis.